Table 2.

Total number of mutations identified in the patients' cancer genome.

Mutated gene	Number of patients with mutation	Mutation type $\text{(red: damaging mutations;}$ $\text{blue: potentially damaging mutations)}$	Patient code
RAS	6	$\text{c35G>A}$ $\text{c.181C>A}$ $\text{c.34G>C}$ $\text{c.35G>T}$	CY100 CY102 CY103 CY106, CY107, CY112
TP53	4	$\text{c.818G>A}$ $\text{c.202G>T}$ $\text{c.586C>T}$ $\text{c.504del}$	CY101 CY108 CY112 CY114
PIK3CA	3	$\text{c.263G>A}$ $\text{c.1636C>A}$ $\text{c.3140A>G}$	CY102 CY108 CY114
TPMT	2	$\text{c.719A>G}$ $\text{c.460G>A}$	CY103 CY112
RB1	1	$\text{c.2148\_2156del}$	CY104
GNAS	1	$\text{c.2531G>A}$	CY105
CDKN2A	1	$\text{c.210\_211insC}$	CY106
JAK3	1	$\text{c.2164G>A}$	CY108
JAK2	1	$\text{c.1666T>G}$	CY108
FGFR4	1	$\text{c.2018G>A}$	CY108
SMO	1	$\text{Genomic amplification}$	CY110
AKT1	1	$\text{c.49G>A}$	CY114
SMAD4	1	$\text{c.346C>T}$	CY114
PMS2	1	$\text{c.1866G>A}$	CY116